Alveolar Macrophage Programming Following Endotoxin Exposure

Last updated: May 2, 2025
Sponsor: National Jewish Health
Overall Status: Active - Recruiting

Phase

N/A

Condition

Respiratory Failure

Lung Injury

Acute Respiratory Distress Syndrome (Ards)

Treatment

bronchoscopy with intrabronchial administration of lipopolysaccharide

Clinical Study ID

NCT03859050
HS-3131
  • Ages 18-50
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Written, informed consent

  2. Age 18-50

Exclusion

Exclusion Criteria:

  1. Current or recent illness (past 2 weeks)

  2. Presence or prior history of cardiac, pulmonary or systemic disease

  3. Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy

  4. American Society of Anesthesiology (ASA) class 2 or greater

  5. Immunocompromised state (HIV, immunoglobulin deficiency, systemicimmunosuppressants)

  6. Use of any inhaled substance, including tobacco, marijuana, e-cigarrettes, cocaine,methamphetamines, or toxic vapors in the past 3 months or greater than 10 pack-yearsmoking history

  7. Alcohol use disorder or greater than 7 drinks/week for women or greater than 14drinks/week for men in the past 3 months

  8. Allergy or prior adverse reaction to lidocaine, midazolam or fentanyl

  9. Abnormal spirometry or electrocardiogram at time of screening

  10. Pregnant (based on urine pregnancy test) or breast feeding

Study Design

Total Participants: 25
Treatment Group(s): 1
Primary Treatment: bronchoscopy with intrabronchial administration of lipopolysaccharide
Phase:
Study Start date:
March 18, 2019
Estimated Completion Date:
July 31, 2032

Connect with a study center

  • National Jewish Health

    Denver, Colorado 80206
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.